Developing new methods for creating important chemical bonds
Harnessing Electrophilic N-Aryl Catalytic Intermediates for Versatile C-N Bond Formation
This study is working on new ways to create important building blocks for medicines by using special nitrogen compounds, which could help make the production of new drugs and therapies easier and more efficient for patients in the future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10728417 on NIH RePORTER |
What this research studies
This research focuses on creating new chemical reactions that allow for the formation of specific bonds in organic compounds, particularly those containing nitrogen. By exploring the unique properties of certain nitrogen-containing intermediates, the research aims to simplify the synthesis of complex molecules that are crucial for pharmaceuticals and other materials that enhance human health. The approach involves innovative techniques to generate and utilize these intermediates, which could lead to more efficient production of vital compounds. Patients may benefit indirectly through the development of new drugs and therapies derived from these improved chemical processes.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals who may require new treatments for various health conditions addressed by novel pharmaceuticals.
Not a fit: Patients with conditions that are not related to the development of new chemical compounds or pharmaceuticals may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new pharmaceuticals that improve health outcomes and quality of life.
How similar studies have performed: While the specific methods being explored may be novel, there is a history of successful research in developing new chemical reactions that have led to significant advancements in drug development.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Driver, Tom G — University of Illinois at Chicago
- Study coordinator: Driver, Tom G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.